What is the 13F Pro Quality Score for PGNY?

13F Pro ranks Progyny, Inc. (PGNY) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View PGNY's current score at https://13fpro.ai/company/PGNY (free sign-up required for the full ranking).

Which hedge funds own the most PGNY stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of PGNY include BlackRock,, FMR, VANGUARD PORTFOLIO MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/PGNY as soon as new 13F filings post.

Where does 13F Pro source PGNY data?

All Progyny, Inc. fundamentals and ownership data come directly from SEC EDGAR. Progyny, Inc. files with the SEC under CIK 1551306. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is PGNY in?

Progyny, Inc. (PGNY) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What are PGNY's largest expenses?

Progyny, Inc.'s latest 10-Q reports these as the largest expense items: Cost of services ($261.2M, +3% YoY); General and administrative ($31.2M, -14% YoY); Sales and marketing ($18.1M, -2% YoY). Sourced directly from SEC EDGAR filing text for Q2 FY2026 (quarter ended June 30, 2026).

How often is PGNY research updated on 13F Pro?

PGNY's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Progyny, Inc.(PGNY)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqmid

Institutional-grade research for retail investors

SEC EDGAR: CIK 1551306 PGNY stock profile & AI dashboard →

13F Pro Quality Score

62.7/100

Rank #691 of 2,961 stocksTOP 25%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

52.1/100

Profitability

57.0/100

Balance Sheet

86.7/100

Earnings Quality

87.1/100

Free Cash Flow

62.8/100

Institutional Flow

93.1/100

Revenue Scale

55.3/100

Dilution Risk

16.0/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why PGNY Scores 63/100

exact factor attribution · 2026-09-11

PGNY's composite is driven by earnings quality and capital efficiency, held back by shareholder dilution. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Earnings quality

+3.7 pts

87th pct

Capital efficiency

+3.7 pts

87th pct

Institutional flow

+2.1 pts

93th pct

Free cash flow

+1.9 pts

63th pct

Profitability

+1.1 pts

57th pct

Scale

+0.8 pts

55th pct

Earnings growth

+0.7 pts

63th pct

Revenue growth

+0.4 pts

52th pct

Shareholder dilution

-1.7 pts

16th pct

Latest change (2026-08-07): 59 → 58 · ↓ Revenue growth 62→47

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

PGNY Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Progyny, Inc. (PGNY), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PGNY at 62.7/100 on a 32-signal composite quality model, placing it at rank #691 of 2,961 stocks — the top 25% of the AI-ranked universe. PGNY scores in the top quartile across institutional flow (93.1), earnings quality (87.1), balance sheet strength (86.7). Shareholder dilution risk is elevated at 16.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Progyny, Inc. reports quarterly revenue of $350.5M, net income of $28.1M, an operating margin of 11.4%. Top institutional holders of PGNY by reported 13-F value include BlackRock, FMR, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. PGNY trades on the Nasdaq exchange and files with the SEC under CIK 1551306. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PGNY daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Progyny, Inc. directly from SEC EDGAR. Progyny, Inc.'s 13F Pro composite quality score has ranged between 54 and 69 since 2022, currently 62.7 — a stable long-term trajectory across 64 quarterly and live scoring snapshots.

✦

Fun facts about Progyny, Inc.

Quirks, history, and lore behind PGNY — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare company · small-cap · listed on Nasdaq · headquartered in New York City.
2
The Numbers
Annual revenue in the range of roughly $1 billion, built almost entirely on contracts with self-insured employers who want to offer richer benefits.
3
The History
Founded in the late 2010s, it went public around 2019 — one of the few healthcare IPOs of that era centered entirely on a single benefits category.
4
The Secret
It doesn't own clinics or employ doctors — it's a benefits management platform that builds curated networks of specialists and handles all the authorization and payment.
5
The Lore
Its clients include some of the largest companies in America, yet most employees only discover it exists when they open their HR benefits portal and see a dedicated fertility benefit for the first time.
6
The Giveaway
This company is essentially the go-to fertility benefits manager for big employers — covering IVF, egg freezing, and surrogacy so that workers don't have to fight with a generic insurer over every treatment cycle.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving PGNY's Business? Latest 10-Q Breakdown

✓ 23/23 datapoints verified

AI-extracted from Progyny, Inc.'s 10-Q filed 2026-08-07 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Progyny grew Q2 revenue 5% YoY to $350.5M while gross margin expanded 180bps to 25.5% and net income rose 64% to $28.1M, aided by lower stock-based compensation.

Biggest Revenue Drivers

Fertility benefits services$230.2M+8% YoY

Increase in number of clients and covered lives, partially offset by the impact of a large client's non-renewal transition period that ended June 30, 2025

Pharmacy benefits services (Progyny Rx)$120.3M+1% YoY

Increase in clients and covered lives, partially offset by the same large client non-renewal impact

Biggest Revenue Drivers

Total revenue: $350.5M+5% YoY

Fertility benefits services$230.2M+8% YoY

Increase in number of clients and covered lives, partially offset by the impact of a large client's non-renewal transition period that ended June 30, 2025

Pharmacy benefits services (Progyny Rx)$120.3M+1% YoY

Increase in clients and covered lives, partially offset by the same large client non-renewal impact

Largest Expense Items

Cost of services$261.2M+3% YoY

Higher medical treatment and pharmacy prescription costs, partially offset by a $3.4M decrease in stock-based compensation and the large client non-renewal impact

General and administrative$31.2M-14% YoY

$5.9M decrease in stock-based compensation as the November 2021 retention grant fully vested in late 2025, partially offset by incremental headcount costs

Sales and marketing$18.1M-2% YoY

$2.6M decrease in stock-based compensation, partially offset by higher other sales and marketing expenses and incremental headcount

Margins: Gross margin rose 180 basis points to 25.5% from 23.7%, driven by ongoing efficiencies in delivery of care management services and lower stock-based compensation expense.

Watch Items from the Filing

No single client accounted for more than 10% of total revenue for the six months ended June 30, 2026, though the filing notes a significant portion of revenue and clients are concentrated in the technology industry.
Revenue growth was tempered by the prior-year loss of a large client whose extended transition-of-care agreement ended June 30, 2025, creating a tougher comp base going forward.
The Consolidated Appropriations Act of 2026 (signed Feb 3, 2026) imposes new PBM disclosure, 100% rebate pass-through, and audit requirements that could affect Progyny Rx's profitability.
Board authorized a new $200M share repurchase program in May 2026 (after completing the $200M November 2025 program); $148.1M of stock was repurchased in the first half of 2026, with $168.5M still available.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$350.5M

Net Income

Q2 2026

$28.1M

Free Cash Flow

Q2 2026

$44.2M

Operating Margin

Q2 2026

11.4%

ROIC

Q2 2026

35.3%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+10.4% YoY

$1.29BFY 2025

FY22 $786.9MFY23 $1.09BFY24 $1.17BFY25 $1.29B

Net Income

+7.7% YoY

$58.5MFY 2025

FY22 $30.4MFY23 $62.0MFY24 $54.3MFY25 $58.5M

Operating Income

+26.4% YoY

$85.3MFY 2025

FY22 $23.3MFY23 $62.2MFY24 $67.5MFY25 $85.3M

EPS (Diluted)

+14.0% YoY

$0.65FY 2025

FY22 $0.30FY23 $0.62FY24 $0.57FY25 $0.65

Total Assets

+22.3% YoY

$742.4MFY 2025

FY22 $543.0MFY23 $756.6MFY24 $607.1MFY25 $742.4M

Op. Cash Flow

+17.4% YoY

$210.2MFY 2025

FY22 $80.4MFY23 $188.8MFY24 $179.1MFY25 $210.2M

Free Cash Flow

+10.4% YoY

$191.8MFY 2025

FY22 $77.2MFY23 $185.2MFY24 $173.7MFY25 $191.8M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$1.29B +10.4%	$1.17B +7.2%	$1.09B +38.3%	$786.9M +57.2%	$500.6M +45.2%	$344.9M
Net Income	$58.5M +7.7%	$54.3M -12.4%	$62.0M +104.4%	$30.4M -53.8%	$65.8M +41.6%	$46.5M
Operating Income	$85.3M +26.4%	$67.5M +8.5%	$62.2M +166.4%	$23.3M -27.8%	$32.3M +287.4%	$8.3M
EPS (Diluted)	$0.65 +14.0%	$0.57 -8.1%	$0.62 +106.7%	$0.30 -54.5%	$0.66 +40.4%	$0.47
Total Assets	$742.4M +22.3%	$607.1M -19.8%	$756.6M +39.3%	$543.0M +51.6%	$358.1M +41.0%	$253.9M
Operating Cash Flow	$210.2M +17.4%	$179.1M -5.1%	$188.8M +134.9%	$80.4M +208.8%	$26.0M -28.1%	$36.2M
Free Cash Flow	$191.8M +10.4%	$173.7M -6.2%	$185.2M +140.0%	$77.2M +222.7%	$23.9M -32.0%	$35.2M

Get alerted when PGNY's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Progyny, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of PGNY

BlackRock, Inc.
$334.4M11,599,921 sh
FMR LLC
$201.9M7,004,280 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$144.7M5,019,465 sh
VANGUARD CAPITAL MANAGEMENT LLC
$92.6M3,210,723 sh
STATE STREET CORP
$87.1M3,022,859 sh
AMERIPRISE FINANCIAL INC
$79.7M2,763,514 sh
FORT WASHINGTON INVESTMENT ADVISORS INC /OH/
$73.5M2,548,164 sh
GEODE CAPITAL MANAGEMENT, LLC
$56.8M1,969,208 sh
CITADEL ADVISORS LLC
$51.5M1,785,717 sh
DIMENSIONAL FUND ADVISORS LP
$48.7M1,688,670 sh

Fund	Value	Shares
BlackRock, Inc.	$334.4M	11,599,921
FMR LLC	$201.9M	7,004,280
VANGUARD PORTFOLIO MANAGEMENT LLC	$144.7M	5,019,465
VANGUARD CAPITAL MANAGEMENT LLC	$92.6M	3,210,723
STATE STREET CORP	$87.1M	3,022,859
AMERIPRISE FINANCIAL INC	$79.7M	2,763,514
FORT WASHINGTON INVESTMENT ADVISORS INC /OH/	$73.5M	2,548,164
GEODE CAPITAL MANAGEMENT, LLC	$56.8M	1,969,208
CITADEL ADVISORS LLC	$51.5M	1,785,717
DIMENSIONAL FUND ADVISORS LP	$48.7M	1,688,670

Companies Similar to PGNY

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

MMSI

MERIT MEDICAL SYSTEMS INC

AI score

Similar quality profile · 11 shared holders

FORT WASHINGTON INVESTMENT ADVISORS INC /OH/WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC MARTINGALE ASSET MANAGEMENT L P

ADUS

Addus HomeCare Corp

AI score

Similar quality profile · 14 shared holders

WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC Dana Investment Advisors, Inc.NORDEA INVESTMENT MANAGEMENT AB

BCPC

BALCHEM CORP

AI score

Similar quality profile · 10 shared holders

WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC TOCQUEVILLE ASSET MANAGEMENT L.P.SEGALL BRYANT & HAMILL, LLC

ANIP

ANI PHARMACEUTICALS INC

AI score

Similar quality profile · 16 shared holders

Soleus Capital Management, L.P.WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC LOOMIS SAYLES & CO L P

PODD

INSULET CORP

AI score

Similar quality profile · 15 shared holders

Soleus Capital Management, L.P.BAILLIE GIFFORD & CO JUPITER ASSET MANAGEMENT LTD

CHE

CHEMED CORP

AI score

Similar quality profile · 14 shared holders

FORT WASHINGTON INVESTMENT ADVISORS INC /OH/River Road Asset Management, LLC JUPITER ASSET MANAGEMENT LTD

LFST

LifeStance Health Group, Inc.

AI score

Similar quality profile · 11 shared holders

LOOMIS SAYLES & CO L P First Eagle Investment Management, LLC Moran Wealth Management, LLC

MEDP

Medpace Holdings, Inc.

AI score

Similar quality profile · 11 shared holders

BAILLIE GIFFORD & CO NORDEA INVESTMENT MANAGEMENT AB FORT WASHINGTON INVESTMENT ADVISORS INC /OH/

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put PGNY on your watchlist

Track score changes the day Progyny, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is PGNY a good stock to buy?

13F Pro's AI-powered analysis of Progyny, Inc. (PGNY) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PGNY are available on the PGNY stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. PGNY is classified as a mid company.

Which hedge funds own PGNY?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PGNY. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Progyny, Inc.'s investment landscape.